What gives ,
1.Merck licensing deal
2.Merck buyout
Surely if the 1st line upcoming NSCLC data is good, Merck stumps up.Big Pharma don’t like sharing,this is beginning to look like a must have for Merck,they’ll want to tie the technology up one way or another.
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-22
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.8¢ |
Change
-0.008(2.54%) |
Mkt cap ! $413.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.0¢ | $1.330M | 4.605M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 378130 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 258595 | 42 |
View Market Depth
| Last trade - 15.05pm 06/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |